Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 2/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 2/20 | 1.00 |
| ▸ | CILK1 | Q9UPZ9 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | DDX42 | Q86XP3 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 0.98 |
| ▸ | CDK2 | P24941 | 12/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL290347 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29387962 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29505152 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL6119675 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663219 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL23683025 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL17348307 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL665749 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL31702788 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL291157 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196680-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2021-07-01 | — | — | US | claimed |
| US-20190167639-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2019-06-06 | — | — | US | claimed |
| EP-2714031-B1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | PIRAMAL ENTPR LTD (IN) | 2018-05-23 | — | — | EP | claimed |
| US-20170189378-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2017-07-06 | — | — | US | claimed |
| US-20170071908-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | PIRAMAL ENTPR LTD (IN) | 2017-03-16 | — | — | US | claimed |
| EP-2802323-B1 | PYRROLIDINE-SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | PIRAMAL ENTPR LTD (IN) | 2016-08-10 | — | — | EP | claimed |
| WO-2016012982-A1 | COMBINATION THERAPY FOR THE TREATMENT OF RESISTANT BREAST CANCER | Piramal Enterprises Limited (IN) | 2016-01-28 | — | — | WO | claimed |
| US-8906953-B2 | Pyrrolidine substitute flavones for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2014-12-09 | — | — | US | claimed |
| WO-2014140695-A1 | SOLID ORAL FORMULATION OF A PYRROLIDINE SUBSTITUTED FLAVONE COMPOUND | Piramal Enterprises Limited (IN) | 2014-09-18 | — | — | WO | claimed |
| WO-2014128524-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | claimed |
| WO-2014128523-A1 | A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | claimed |
| US-20140142159-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2014-05-22 | — | — | US | claimed |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-12 | — | — | US | claimed |
| EP-2538941-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-13 | — | — | US | claimed |
| WO-2011104584-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | claimed |
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | claimed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | claimed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | disclosed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20250195467-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2025-06-19 | — | — | US | disclosed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | disclosed |
| US-12076309-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2024-09-03 | — | — | US | disclosed |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2024-05-23 | — | — | US | disclosed |
| CN-117731786-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-111053768-B | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2023-12-12 | — | — | US | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | disclosed |
| US-20220023263-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2022-01-27 | — | — | US | disclosed |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2021-12-23 | — | — | US | disclosed |
| US-11160789-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2021-11-02 | — | — | US | disclosed |
| CN-113412127-A | Mesoporous silica particle compositions for viral delivery | 诺华股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-113272281-A | ALK5 inhibitor for treating myelodysplastic syndrome | 大日本住友制药肿瘤公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210196680-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2021-07-01 | — | — | US | disclosed |
| CN-112955188-A | Method of treating neuroendocrine tumors | 先进加速器应用公司 | 2021-06-11 | — | — | CN | disclosed |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2021-05-18 | — | — | US | disclosed |
| US-10980776-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | Piramal Enterprises Limited (IN) | 2021-04-20 | — | — | US | disclosed |
| CN-112584875-A | Stabilized, concentrated solutions of radionuclide complexes | 先进加速器应用公司 | 2021-03-30 | — | — | CN | disclosed |
| EP-3148532-B1 | PHARMACEUTICAL COMBINATION COMPRISING A CDK INHIBITOR AND A THIOREDOXIN REDUCTASE INHIBITOR FOR THE TREATMENT OF CANCER | PIRAMAL ENTPR LTD (IN) | 2021-03-03 | — | — | EP | disclosed |
| US-20200289465-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2020-09-17 | — | — | US | disclosed |
| US-10688079-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20200138782-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2020-05-07 | — | — | US | disclosed |
| CN-111053768-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-110831619-A | Biomarkers and CAR T cell therapy with enhanced efficacy | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10555931-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2020-02-11 | — | — | US | disclosed |
| CN-110582509-A | Treatment of cancer using chimeric T cell receptor proteins with multispecific properties | 诺华股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2019-09-19 | — | — | US | disclosed |
| US-20190167639-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2019-06-06 | — | — | US | disclosed |
| EP-3019166-B1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | PIRAMAL ENTPR LTD (IN) | 2019-05-08 | — | — | EP | disclosed |
| US-10245251-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | Piramal Enterprises Limited (IN) | 2019-04-02 | — | — | US | disclosed |
| US-20180369200-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2018-12-27 | — | — | US | disclosed |
| US-10098869-B2 | Compounds for the treatment of cancers associated with human papillomavirus | Piramal Enterprises Limited (IN) | 2018-10-16 | — | — | US | disclosed |
| EP-2714031-B1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | PIRAMAL ENTPR LTD (IN) | 2018-05-23 | — | — | EP | disclosed |
| US-20170189378-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2017-07-06 | — | — | US | disclosed |
| US-20170157090-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2017-06-08 | — | — | US | disclosed |
| US-20170112809-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170071908-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | PIRAMAL ENTPR LTD (IN) | 2017-03-16 | — | — | US | disclosed |
| EP-2427188-B1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | PIRAMAL ENTPR LTD (IN) | 2016-08-10 | — | — | EP | disclosed |
| EP-2802323-B1 | PYRROLIDINE-SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | PIRAMAL ENTPR LTD (IN) | 2016-08-10 | — | — | EP | disclosed |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2016-05-19 | — | — | US | disclosed |
| EP-3019166-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016012982-A1 | COMBINATION THERAPY FOR THE TREATMENT OF RESISTANT BREAST CANCER | Piramal Enterprises Limited (IN) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015004636-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2015-01-15 | — | — | WO | disclosed |
| US-8906953-B2 | Pyrrolidine substitute flavones for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20140348950-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2014-11-27 | — | — | US | disclosed |
| US-8895605-B2 | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | Piramal Enterprises Limited (IN) | 2014-11-25 | — | — | US | disclosed |
| EP-2802323-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2014-11-19 | — | — | EP | disclosed |
| WO-2014140695-A1 | SOLID ORAL FORMULATION OF A PYRROLIDINE SUBSTITUTED FLAVONE COMPOUND | Piramal Enterprises Limited (IN) | 2014-09-18 | — | — | WO | disclosed |
| US-8822526-B2 | Synergistic pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2014-09-02 | — | — | US | disclosed |
| WO-2014128523-A1 | A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014128524-A1 | AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES | Piramal Enterprises Limited (IN) | 2014-08-28 | — | — | WO | disclosed |
| EP-2046738-B1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL ENTPR LTD (IN) | 2014-06-11 | — | — | EP | disclosed |
| US-20140142159-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2014-05-22 | — | — | US | disclosed |
| EP-2723449-A2 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2014-04-30 | — | — | EP | disclosed |
| US-20140112918-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2014-04-24 | — | — | US | disclosed |
| US-8563596-B2 | Enantiomerically pure compounds for the treatment of proliferative disorders | Piramal Enterprises Limited (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-12 | — | — | US | disclosed |
| WO-2013105056-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | Piramal Enterprises Limited (IN) | 2013-07-18 | — | — | WO | disclosed |
| CN-101677567-B | Synergistic pharmaceutical combination for the treatment of cancer | NICHOLAS PIRAMAL INDIA LTD | 2013-06-19 | — | — | CN | disclosed |
| EP-2538941-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012176163-A2 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | Piramal Enterprises Limited (IN) | 2012-12-27 | — | — | WO | disclosed |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2012164497-A1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | Piramal Enterprises Limited (IN) | 2012-12-06 | — | — | WO | disclosed |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2012-02-23 | — | — | US | disclosed |
| EP-2154971-B1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011104584-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| EP-2041121-B1 | AN ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINE-SUBSTITUTED FLAVONES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-07-27 | — | — | EP | disclosed |
| US-20110151469-A1 | INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-23 | — | — | US | disclosed |
| US-7951961-B2 | Enantioselective synthesis of pyrrolidines substituted with flavones, and intermediates thereof | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-31 | — | — | US | disclosed |
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | disclosed |
| US-20100305057-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | disclosed |
| US-20100113803-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINES SUBSTITUTED WITH FLAVONES, AND INTERMEDIATES THEREOF | Piramal Enterprises Limited (IN) | 2010-05-06 | — | — | US | disclosed |
| EP-2154971-A2 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Life Sciences Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | disclosed |
| EP-2041121-A1 | AN ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINE-SUBSTITUTED FLAVONES | Piramal Life Sciences Limited (IN) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008139271-A2 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008007169-A1 | AN ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINE-SUBSTITUTED FLAVONES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023263-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20170157090-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-10098869-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK9 8/4885 |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CCNI | CDK4 4/4885CDK1 2/4885CDK9 9/4885 |
| US-20170189378-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-10245251-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-20100113803-A1 | ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINES SUBSTITUTED WITH FLAVONES, AND INTERMEDIATES THEREOF | CCNI, CDKN1A, CDK2 | CDK4 8/4885CDK1 4/4885CDK9 22/4885 |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | CDK4 5/4885CDK1 3/4885CDK9 2/4885 |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | CCNI, CCNK, CDK3 | CDK4 21/4885CDK1 13/4885CDK9 7/4885 |
| US-10980776-B2 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | CCNI, CDK1, CDKL1 | CDK4 7/4885CDK1 2/4885CDK9 4/4885 |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, SYVN1, PAH | CDK4 1833/4885CDK1 842/4885CDK9 2540/4885 |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK9 8/4885 |
| US-12076309-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK9 8/4885 |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK9 8/4885 |
| US-20190167639-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK1 3/4885CDK9 8/4885 |
| US-20200289465-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20250195467-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20140348950-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | SI, MUC1, PCNA | CDK4 1174/4885CDK1 822/4885CDK9 380/4885 |
| US-20100305057-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | CDK4, CDK1, CDK3 | CDK4 1/4885CDK1 2/4885CDK9 13/4885 |
| US-20140112918-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CDK6 | CDK4 15/4885CDK1 2/4885CDK9 28/4885 |
| US-20180369200-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20210196680-A1 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | CDK1, CDK4, CDK11B | CDK4 2/4885CDK1 1/4885CDK9 7/4885 |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | CCNI, CDK1, CCNA1 | CDK4 7/4885CDK1 2/4885CDK9 51/4885 |
| US-20170071908-A1 | PYRROLIDINE- SUBSTITUTED FLAVONE DERIVATIVES FOR PREVENTION OR TREATMENT OF ORAL MUCOSITIS | SI, PCNA, PMS2 | CDK4 1400/4885CDK1 906/4885CDK9 490/4885 |
| US-10688079-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-11160789-B2 | Compounds for the treatment of cancers associated with human papillomavirus | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
| US-20140142159-A1 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS | TP53, VHL, POLI | CDK4 19/4885CDK1 139/4885CDK9 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.